CRISPR Therapeutics AG

CRSP • Biotechnology

$55.79

▼ -0.70 (-1.24%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$5.38B

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Nivel de deuda manejable · 0.21Liquidez saludable · 13.32Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 12 ago 2026, 12:38 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$55.79

Change-1.24%

Shares Out96.51M

Market Cap$5.38B

Enterprise Value$3.80B

52W Range44.12 - 78.48

Beta1.74

P/E-11.94

P/S402.07

P/B3.08

P/FCF-14.50

EV/Sales284.04

Price$55.79

Change-1.24%

Shares Out96.51M

Market Cap$5.38B

Enterprise Value$3.80B

52W Range44.12 - 78.48

Beta1.74

P/E-11.94

P/S402.07

P/B3.08

P/FCF-14.50

EV/Sales284.04

EV/EBITDA-7.71

EV/FCF-10.24

Earnings Yield-8.38%

FCF Yield-6.90%

Dividend Yield0.00%

Gross Margin-65.37%

Oper. Margin-161.91%

Profit Margin-165.70%

Debt/Eq0.21

Current Ratio13.32

Quick Ratio13.32

Target$67.83

Target Upside21.58%

Target Median$68.00

Target Range55.00 - 80.00

Volume1.04M

Avg Volume1.71M

EPS Surprise-0.10

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

51/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.21Liquidez saludable · 13.32Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

CRSP

Analyst sentiment

Based on 38 analyst votes · 2026-09-05

76/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-12

Bajo

$55.00

Promedio

$70.63

Mediana

$76.00

Alto

$82.00

Resumen de la compañía

IPO: 10/19/2016

Industria: Biotechnology

P/B i: 3.08

Deuda / Patrimonio i: 0.21

Margen operativo: -16191.40%

Margen neto: -16569.77%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.21

Ratio corriente: 13.32

Ratio rápido: 13.32

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Prasad Raju

Transacción: 08/07/2026

VENTA

Cambio

-750

Precio

Not reported

Presentación

08/11/2026

Tipo

VENTA

Treco Douglas A

Transacción: 06/05/2026

COMPRA

Cambio

+13,000

Precio

$51.84

Presentación

06/09/2026

Tipo

COMPRA

Rommel Christian

Transacción: 06/05/2026

COMPRA

Cambio

+13,000

Precio

$51.84

Presentación

06/09/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Prasad Raju	VENTA	-750	Not reported	08/07/2026	08/11/2026
Treco Douglas A	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Rommel Christian	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Morrison Briggs	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Mahatme Sandesh	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
High Katherine A	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Greene John	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Fleming Harold Edward	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Fardis Maria	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Behbahani Ali	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
George Simeon	COMPRA	+13,000	$51.84	06/05/2026	06/09/2026
Prasad Raju	COMPRA	+19,500	Not reported	05/29/2026	06/02/2026
Patel Naimish	COMPRA	+22,000	Not reported	05/29/2026	06/02/2026
KASINGER JAMES R.	COMPRA	+17,000	Not reported	05/29/2026	06/02/2026
Patel Naimish	VENTA	-3,786	$55.62	05/29/2026	06/01/2026
Patel Naimish	VENTA	-10,000	Not reported	05/28/2026	06/01/2026
Patel Naimish	COMPRA	+10,000	Not reported	05/28/2026	06/01/2026
Prasad Raju	VENTA	-3,708	$46.78	03/23/2026	03/24/2026
Kulkarni Samarth	VENTA	-10,020	$46.78	03/23/2026	03/24/2026
KASINGER JAMES R.	VENTA	-3,182	$46.78	03/23/2026	03/24/2026

Sobre la compañía

CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Fuente - Link

Competidores

ACLX AKRO ARWR CYTK KRYS MTSR NUVL PCVX PTCT TGTX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case

CRISPR Therapeutics transitioned from speculative biotech to commercial stage with FDA approval of CASGEVY, validating its CRISPR/Cas9 platform. CRSP's pipeline targets multi-billion-dollar markets in cardiovascular, autoimmune, oncology, and diabetes, supported by a robust IP portfolio and major pharma partnerships. Current $5.6B market cap and $1.78B net cash position offer acquisition appeal, but most pipeline assets remain early stage and execution risks persist.

Seeking Alpha

2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026

CRISPR Therapeutics' only approved product may experience increased demand. The biotech could also see significant clinical progress with some key candidates.

The Motley Fool

Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Benzinga

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean reduction in triglycerides (TG) of 48% (maximum 78%), and a mean reduction of low-density lipoprotein (LDL) of 53% (maximum 84%) at the highest dose- -CTX310 was well tolerated with no treatment-related serious adverse events, no ≥Grade 3 changes in liver transaminases, and no additional treatment-related adverse events since the previous update- -Findings simultaneously published in The New England Journal of Medicine entitled “Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310”- ZUG, Switzerland and BOSTON, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310 ®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3. A single-course treatment with CTX310 produced deep and durable reductions in circulating ANGPTL3, triglycerides (TG), and low-density lipoprotein (LDL) that were sustained through one year of follow-up.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-04	-1.18324	-1.28	-0.09676
2026-02-12	-1.15	-1.37	-0.22
2025-11-10	-1.26	-1.17	0.09
2025-08-04	-1.47	-1.29	0.18
2025-05-06	-1.27	-1.58	-0.31
2025-02-11	-1.15	-0.44	0.71
2024-11-05	-1.33	-1.01	0.32
2024-08-05	-1.37	-1.49	-0.12
2024-05-08	-1.63	-1.43	0.2
2024-02-21	-0.07	1.1	1.17
2023-11-06	-1.98	-1.41	0.57
2023-08-07	-2.18	-0.98	1.2